[노벨티노빌리티 상장 리부트]③ c키트 플랫폼, 조기 LO 모델 시험대

Novelti Nobility's IPO restart hinges on proving its c-Kit platform can achieve repeatable success in early-stage technology licensing (LO) across diverse therapeutic areas. The critical challenge is delivering differentiated data packages that address unmet market needs while demonstrating platform extensibility from immunoinflammatory diseases to oncology and ophthalmology. Success with NN2802, NN3201, and NN4101 would establish a new business model paradigm for platform-driven biotech companies seeking to monetize assets before full clinical development.